Risk factors for dysgeusia during chemotherapy for solid tumors: a retrospective cross-sectional study

ConclusionCycles of chemotherapy, sex, uterine cancer, head and neck tumors, testicular cancer, ifosfamide, docetaxel, paclitaxel, pertuzumab, bevacizumab, and dacarbazine increase the risk of dysgeusia.
Source: Supportive Care in Cancer - Category: Cancer & Oncology Source Type: research